Nachrichten zur Biogen Inc. Aktie

Opening Bell: Steigende Kurse vor Thanksgiving; Best Buy, Zoom Video, ExxonMobil, Baidu, Biogen, Vertex, Tesla im Fokus

An der Wall Street kündigt sich am Dienstag eine freundliche Handelseröffnung an. Der Dow Jones steigt 30 Minuten vor dem…

Global Hemoglobinopathies Market Report to 2031 - Featuring Abbott Laboratories, Alnylam Pharmaceuticals, Biogen Idec and Bluebird Among Others

DUBLIN, Nov. 21, 2022 /PRNewswire/ -- The "Hemoglobinopathies Market By Type, By Therapy, By Distribution Channel: Global Opportunity Analysis and…

Teva names former Sandoz chief Richard Francis as new CEO

Teva Pharmaceutical Industries Ltd. on Monday said its current CEO Kåre Schultz will retire on Dec. 31. Robert Francis,…

Is Biogen (BIIB) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to…

Biogen: Kursziel erhöht

New York (www.aktiencheck.de) - Rating-Update: Jay Olson, Analyst von Oppenheimer, stuft die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN: 789617, Ticker-Symbol:…

Biogen: Kursziel angehoben

Charlotte, NC (www.aktiencheck.de) - Rating-Update: Robyn Karnauskas, Analystin von Truist, stuft die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN: 789617, Ticker-Symbol:…

Dow Jones & Co rutschen ins Minus: Merck & Co, Visa, Moderna, Biogen, Netflix und Baidu stark, Hasbro Top-Verlierer – der Tag an der Wall Street

Die US-Börsen sind am Montag auf Berg- und Talfahrt gegangen. Zeitweise gelang es ihnen, an ihre Rally aus der vergangenen…

Moderna, Biogen rise; Oatly, Dentsply fall

Stocks that traded heavily or had substantial price changes Monday: Moderna, Biogen rise; Oatly, Dentsply fall...…

Netflix startet durch: Ausbruch auf neues 6-Monatshoch

Die Aktie von Netflix setzt auch zu Wochenbeginn ihre starke Entwicklung der vergangenen Tage fort. Rund eine Stunde vor Handelsende…

One Alzheimer’s drug has failed, but investors are still betting on Biogen and Lilly treatments

Biogen stock is rising as investors double down on the company’s promising yet still experimental treatment for Alzheimer’s disease....…

Blitz-Update: Dow & Co nach Rally stabil – Pharmawerte im Fokus, Merck & Co, Johnson & Johnson, Biogen Top-Gewinner, Apple und Microsoft mit Verlusten

Nach der jüngsten Rally herrscht am Montag an den US-Börsen Zurückhaltung. Zugleich aber zeigen sich die Anleger recht entspannt. Der…

Biogen in Pole Position After Roches Alzheimers Drug Disappoints

Swiss pharmaceutical company Roche said the drug failed to slow patients' clinical decline, in contrast to positive results from Biogen…

Thinking about trading options or stock in Alibaba, Biogen, Exxon Mobil, Eli Lilly, or Apple?

NEW YORK, Nov. 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BABA, BIIB, XOM, LLY, and AAPL. Click…

Nasdaq, S&P 500 Futures Pullback At Start Of New Trading Week As Rate Fears Return To Haunt; AMD, Tesla, Biogen, Eli Lilly, JD In Focus

The major U.S. index futures are pointing to a moderately lower opening on Wall Street on Monday, as optimism following…

Why Shares Of Eli Lilly And Biogen Are Rallying Today

Shares of Biogen Inc. (NASDAQ: BIIB) and Eli Lilly & Co. (NYSE: LLY) are rallying in premarket trading on Monday…

Roche Sinks as Alzheimers Drug Disappoints. Biogen is Gaining.

The Swiss pharma company said the drug failed to slow patients' clinical decline, in contrast to positive results from Biogen…

Biogen shares jump 4.7% premarket on hopes for its Alzheimers treatment lecanemab

Biogen Inc. shares rose 4.7% in premarket trade Monday, after MorphoSys and partner Roche said a trial of a…

Morphosys: Aktie nach Alzheimer-Flop bei Roche auf Talfahrt

Im milliardenschweren Rennen um ein wirksames Alzheimer-Medikament hat der Morphosys-Partner Roche einen heftigen Rückschlag erlitten. Die Morphosys-Papiere brechen um knapp…

MorphoSys -28%: SD-Leser wurden vor dem Risiko gewarnt

Die MorphoSys-Aktie (WKN: 663200) bricht am Vormittag brutal ein um mehr als -28% auf rund 15 €. Lizenzpartner Roche hat…

Biogen tabs veteran pharma leader Viehbacher as next CEO

Biogen has picked former Sanofi CEO Christopher Viehbacher to become its next leader, as the drug developer continues to recover…

Biogen Picks Drug-Industry Veteran Viehbacher as Its Next CEO

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

Biogen Names Viehbacher New CEO

The veteran pharmaceutical executive takes charge of after the failed launch of Biogens once-promising Alzheimers disease drug Aduhelm....…

Biogen Appoints Christopher Viehbacher As President And CEO

WESTON (dpa-AFX) - Biotechnology company Biogen Inc. (BIIB) announced Thursday that its Board of Directors has appointed Christopher Viehbacher as…

Biogen names former Sanofi chief as new CEO, shares rise

Biogen Inc. stock rose 1% in premarket trades on Thursday after Christopher A. Viehbacher was named president and chief…

Biogen names Christopher Viehbacher as CEO

...(Reuters) -Biogen Inc on Thursday named Christopher Viehbacher as its......…

Biogen Names Christopher Viehbacher President and Chief Executive Officer

Distinguished Industry Leader Brings Extensive International Experience in Large Pharmaceutical and Entrepreneurial Biotech Companies Distinguished Industry Leader Brings Extensive International…

Form 8-K BIOGEN INC. For: Nov 10

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Former J&J exec no longer seen as frontrunner for Biogen CEO position - STAT

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Alzheimer-Medikament: Wettlauf der Pharmakonzerne Biogen, Roche und Eli Lilly

Langjährige Forschungen nach einem wirksamen Alzheimer-Medikament stehen vor dem Durchbruch. Pharmakonzerne wie Biogen, Roche oder Eli Lilly positionieren sich auf…

Biogen: Kursziel erhöht

New York (www.aktiencheck.de) - Rating-Update: Philip Nadeau, Analyst von Cowen and Company, stuft die Biogen-Aktie (ISIN: US09062X1037, WKN: 789617, Ticker-Symbol: IDP,…

Biogen: Upgrade

New York (www.aktiencheck.de) - Rating-Update: Salveen Richter, Analystin von Goldman Sachs, stuft die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN:…

Biogen: Kurszielerhöhung

New York (www.aktiencheck.de) - Rating-Update: Das Anlagevotum von Matthew Harrison, Analyst von Morgan Stanley, für die Aktie von Biogen Inc. (ISIN:…

Biogen: Kursziel angehoben

New York (www.aktiencheck.de) - Rating-Update: Andrew Fein, Analyst von H.C. Wainwright & Co, stuft die Aktie von Biogen Inc. (ISIN: US09062X1037,…

Insiderhandel: EVP Chief Legal Off & Corp Sec verkauft Aktien von Biogen im Wert von 1.552.832$

Alexander, Susan H. - Vorstand - Tag der Transaktion: 2022-10-27...…

Friday’s Top Analysts Upgrades and Downgrades: AGNC Investment, Biogen, Carnival, Lithium Americas, Meta Platforms, Seagate, Waste Management and More

Fridays top analyst upgrades and downgrades included AGNC Investment, Biogen, Cano Health, Carnival, Lithium Americas, Meta Platforms, Seagate Technology, Vertiv,…

Nach dem Flop mit dem Alzheimer-Medikament Aduhelm herrscht in der Solothurner Biotech-Fabrik von Biogen Flaute. Dennoch keimt neue Hoffnung auf

Der US-Konzern Biogen steht nach dem Debakel bei der Lancierung seines ersten Alzheimer-Präparats unter Druck. Dank einem vielversprechenden zweiten Produkt bietet…

Stocks making the biggest moves midday: Harley-Davidson, Visa, Microsoft, Biogen and more

These are the stocks posting the largest moves in midday trading....…

Biogen raised to Buy at Goldman Sachs as Alzheimer’s prospects return

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Is Biogen a Buy After It Boosted Guidance?

Theres a much bigger story for this biotech than its improved 2022 outlook....…

Biogen: Kursziel angehoben

New York (www.aktiencheck.de) - Rating-Update: Michael Yee, Analyst von Jefferies & Co, stuft die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN:…

Biogen (BIIB) Beats on Q3 Earnings & Sales, Raises 2022 Outlook

Biogen (BIIB) beats third-quarter estimates for earnings and sales. Stock rises in pre-market as management raises the companys full-year 2022…

Biogen and Eisai make plans to take another Alzheimer’s drug to the FDA

The companies said last month that their new experimental therapy, called lecanemab, slowed cognitive decline by 27% in a Phase…

Biogen Inc. (BIIB) Surpasses Q3 Earnings and Revenue Estimates

Biogen Inc. (BIIB) delivered earnings and revenue surprises of 15.50% and 1.60%, respectively, for the quarter ended September 2022. Do…

Biogen Lifts Profit Estimates. Stock Rises.

Biogen raised its earnings per share estimate to $16.50 to $17.15, up from the previously estimated $15.25 to $16.75 range....…

Biogen Raises 2022 Guidance

WESTON (dpa-AFX) - Biogen Inc. (BIIB) said, for full year 2022, the company now projects non-GAAP EPS of $16.50 to…

Biogen beats revenue expectations in the third quarter

Biogen's stock was up 0.7% in premarket trading on Tuesday after it beat expectations for earnings and revenue…

Biogen sales fall 9.7% on Tecifdera competition

...Oct 25 (Reuters) - Biogen Inc reported a 9.7% drop in quarterly sales......…

UPDATE 1-Biogen raises full-year profit forecast on cost control

...(Adds details on forecast, background) Oct 25 (Reuters) - Biogen Inc......…

Biogen raises full-year profit forecast on cost control

...(Reuters) -Biogen Inc on Tuesday raised its full-year profit forecast......…

Where Biogen Stands With Analysts

Over the past 3 months, 15 analysts have published their opinion on Biogen (NASDAQ:BIIB) stock. These analysts are typically employed…